LIfT BioSciences, a leading-edge biotech firm gearing up to kick off clinical trials for its novel allogeneic innate cell therapy, has unveiled its latest expansion in manufacturing and clinical activities with the establishment of its Galway-based subsidiary, Eolaíocht Bhitheach LIfT Teoranta, in Ireland. This development marks a pivotal advancement for LIfT as it secures its foothold within the European Union (EU). Operations in Galway will be executed in concert with the University of Galway and HookeBio, receiving backing from Údarás na Gaeltachta.
This tactical growth into the EU enhances LIfT’s international reach, emphasizing the company’s fervor for ceaseless research and cutting-edge innovations. With its main office located in London, UK, the new subsidiary in Galway amplifies the company’s research capabilities at the clinical stage and its manufacturing efficiency, allowing engagement with Ireland’s rich resources in biotechnology.
Alex Blyth, CEO of LIfT BioSciences, stated: “Our establishment in Galway signifies a vital component of LIfT’s growth initiatives, augmenting our proficiency and global outreach. Our allegiance to Ireland’s supportive scientific landscape aligns perfectly with our aims following our Series A financing, as we get ready to commence clinical trials for our pioneering neutrophil-based immuno-cell therapy. We are determined to tackle solid tumour drug resistance to better the lives of cancer patients and appreciate the Irish Government’s shared vision.”
Teresa Burke, Project Manager at Eolaíocht Bhitheach LIfT Teoranta, expressed her enthusiasm: “Joining LIfT BioSciences’s Irish branch as project manager is incredibly motivating. This expansion opens up collaboration avenues with industry forerunners, and I eagerly anticipate contributing to this exciting journey.”
Tomás Ó Síocháin, CEO of Údarás na Gaeltachta, shared: “We cordially welcome LIfT BioSciences’s new Galway subsidiary, Eolaíocht Bhitheach LIfT Teoranta. This cooperation outlines regional capabilities with potential global biotech impact. We look forward to supporting LIfT’s groundbreaking cancer therapies, enriching our life sciences.”
Professor Martin O’Donnell, from the University of Galway, remarked: “Galway’s Eolaíocht Bhitheach LIfT Teoranta symbolizes productive collaboration between LIfT BioSciences, HookeBio, Údarás na Gaeltachta, and the University of Galway. This partnership propels advanced cell therapies and empowering research forward.”
Dr. Mark Lyons, CEO of HookeBio, said: “Collaborating with LIfT on pioneering cancer therapies aligns with our mission to enhance disease therapeutic solutions and minimize animal testing, spotlighting biotech sector resilience and growth.”
This update coincides with LIfT BioSciences’s recent announcement of securing £10 million in the first round of Series A funding to advance its groundbreaking innate cell therapy. LIfT’s innovative IMAN product is engineered to counteract treatment resistance and recognize tumour cells with its unique innate antigen-independent threat pattern recognition, rejuvenating the immune response for sustained anti-cancer effects. LIfT employs its proprietary Neutrophil-based Leukocyte Infusion Therapy (N-LIfT) platform, working on future iPSC-derived products.
LIfT BioSciences, originating from the UK and Ireland, spearheads the market introduction of an innovative neutrophil cell therapy designed to tackle resistance in solid tumours.